<DOC>
	<DOC>NCT00583791</DOC>
	<brief_summary>The objective of this feasibility study is to investigate the safety of the AMPLATZER Muscular VSD Occluder for the treatment of muscular ventricular septal defects, which are hemodynamically significant and are either isolated or in conjunction with other congenital heart defects in infants and children.</brief_summary>
	<brief_title>Closure of Muscular Ventricular Septal Defects With The AMPLATZERÂ® Muscular VSD Occluder</brief_title>
	<detailed_description />
	<criteria>Patients with hemodynamically significant muscular VSD's (demonstrated by echocardiography or angiography), either isolated or in conjunction with other congenital heart defects Age &lt; 18 years old Less than 4 mm distance from the semilunar (aortic and pulmonary) and atrioventricular valves (mitral and tricuspid) Patients with severely increased pulmonary vascular resistance above 7 woods units and a righttoleft shunt and documented irreversible pulmonary vascular disease Patients with perimembranous (close to the aortic valve) VSD Patients &lt; 3 kg Patients with sepsis (local/generalized) Patients with gastritis, gastric ulcer, duodenal ulcer, bleeding disorders etc. and other contraindications to aspirin therapy unless other antiplatelet agents can be administered for 6 months Inability to obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>muscular</keyword>
	<keyword>ventricular</keyword>
	<keyword>septal</keyword>
	<keyword>defects</keyword>
	<keyword>VSD</keyword>
</DOC>